Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical is poised for long-term success due to its diversified portfolio of differentiated products in the high-demand areas of ADHD and pain management. The company's strategy of licensing and acquiring products has resulted in a strong pipeline and steady revenue growth. Although there are potential risks related to generic competition and reimbursement/pricing dynamics, Collegium has a solid financial foundation and is focused on expanding through strategic business development initiatives. Additionally, the company's 2026 guidance highlights the strength of its key product, Jornay PM, and the durability of its pain portfolio, providing confidence in its long-term outlook.

Bears say

Collegium Pharmaceutical is a diversified biopharmaceutical company facing significant competition from established products and generics, leading to potential payor reimbursement and access challenges. Additionally, the company is heavily reliant on third-party suppliers, which could result in disruptions or delays in product manufacturing. This could negatively impact the company's top-line growth and profitability. Despite expected growth in Jornay PM sales, the company's high operating cash flow margin may not be sustainable without continued capital deployment and business development opportunities.

Collegium Pharmaceutical (COLL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Collegium Pharmaceutical (COLL) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.